FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367721052> ?p ?o ?g. }

• W4367721052 abstract "<h3>Background and Importance</h3> Acquired haemophilia A is a coagulation disorder in which antibodies against factor VIII are produced, interfering with its activity and leading to potentially severe bleeding. Among numerous causes, cancer is a prevailing one. First-line haemostatic treatment until inhibitor eradication consists of bypass agents, including recombinant factor VII activated (rFVIIa) or activated prothrombin complex concentrates (aPCC). <h3>Aim and Objectives</h3> We present the case of a 70-year-old male patient diagnosed with metastatic prostate cancer who went to the emergency department of a tertiary referral hospital due to an acute-onset extensive hematoma on the right thigh, with neither personal nor family history of haemophilia. <h3>Material and Methods</h3> The patient was diagnosed with paraneoplasic acquired haemophilia. Therefore, immunosuppressive (methylprednisolone + cyclophosphamide) and haemostatic treatment (rFVIIa at 5 mg every 8h) was initiated. 9 days in, off-label use of emicizumab was requested, intended to guarantee a haemostatic level that would allow outpatient management. Emicizumab was administered subcutaneously at 3 mg/kg weekly over 4 weeks and then fortnightly over 16 weeks between January 13th and May 25th, 2022. Haemostatic was monitored daily during hospitalisation and weekly after discharge through determination of inhibitor activity (Bethesda Units, UB) and FVIII activity (bovine based Chromogenic Factor VIII assay, UI) in blood samples. <h3>Results</h3> The patient was successfully treated until the resolution of bleeding and normalised FVIII levels. Over the treatment with emicizumab as the only haemostatic agent (107 days), 8 subcutaneous injections were administered (cost: €51,255.2). Having used rFVIIa (5 mg every 12 h) would have entailed 214 intravenous infusions, with a direct cost of €618,301.64. Thus, emicizumab treatment meant direct cost saving of €567,046.44. Moreover, contributing factors to overheads as prolonged hospital stay, expenditure on consumables or staffing should be taken into account. Also risk of vascular access complications and quality of life must be considered. <h3>Conclusion and Relevance</h3> Emicizumab has been a safe and cost-effective alternative to rFVIIa in haemorrhage prophylaxis, reducing direct costs by more than 10 times and allowed outpatient management. Self-administration at home represents a major improvement in acquired haemophilia A quality of life. Hospital pharmacy and haematology must collaborate to achieve a rational use of resources and an improvement in quality of life. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest" @default.
• W4367721052 created "2023-05-04" @default.
• W4367721052 creator A5017833801 @default.
• W4367721052 creator A5022639966 @default.
• W4367721052 creator A5033055030 @default.
• W4367721052 creator A5037785856 @default.
• W4367721052 creator A5062695409 @default.
• W4367721052 creator A5066012872 @default.
• W4367721052 creator A5073754705 @default.
• W4367721052 creator A5077404135 @default.
• W4367721052 creator A5080503133 @default.
• W4367721052 creator A5089789014 @default.
• W4367721052 date "2023-03-01" @default.
• W4367721052 modified "2023-09-27" @default.
• W4367721052 title "4CPS-001 Emicizumab in acquired haemophilia type A: a case report" @default.
• W4367721052 doi "https://doi.org/10.1136/ejhpharm-2023-eahp.373" @default.
• W4367721052 hasPublicationYear "2023" @default.
• W4367721052 type Work @default.
• W4367721052 citedByCount "0" @default.
• W4367721052 crossrefType "proceedings-article" @default.
• W4367721052 hasAuthorship W4367721052A5017833801 @default.
• W4367721052 hasAuthorship W4367721052A5022639966 @default.
• W4367721052 hasAuthorship W4367721052A5033055030 @default.
• W4367721052 hasAuthorship W4367721052A5037785856 @default.
• W4367721052 hasAuthorship W4367721052A5062695409 @default.
• W4367721052 hasAuthorship W4367721052A5066012872 @default.
• W4367721052 hasAuthorship W4367721052A5073754705 @default.
• W4367721052 hasAuthorship W4367721052A5077404135 @default.
• W4367721052 hasAuthorship W4367721052A5080503133 @default.
• W4367721052 hasAuthorship W4367721052A5089789014 @default.
• W4367721052 hasBestOaLocation W43677210521 @default.
• W4367721052 hasConcept C126322002 @default.
• W4367721052 hasConcept C141071460 @default.
• W4367721052 hasConcept C2777232031 @default.
• W4367721052 hasConcept C2778385053 @default.
• W4367721052 hasConcept C2778589496 @default.
• W4367721052 hasConcept C2778961111 @default.
• W4367721052 hasConcept C3020110884 @default.
• W4367721052 hasConcept C71924100 @default.
• W4367721052 hasConceptScore W4367721052C126322002 @default.
• W4367721052 hasConceptScore W4367721052C141071460 @default.
• W4367721052 hasConceptScore W4367721052C2777232031 @default.
• W4367721052 hasConceptScore W4367721052C2778385053 @default.
• W4367721052 hasConceptScore W4367721052C2778589496 @default.
• W4367721052 hasConceptScore W4367721052C2778961111 @default.
• W4367721052 hasConceptScore W4367721052C3020110884 @default.
• W4367721052 hasConceptScore W4367721052C71924100 @default.
• W4367721052 hasLocation W43677210521 @default.
• W4367721052 hasOpenAccess W4367721052 @default.
• W4367721052 hasPrimaryLocation W43677210521 @default.
• W4367721052 hasRelatedWork W18576501 @default.
• W4367721052 hasRelatedWork W1969903104 @default.
• W4367721052 hasRelatedWork W2074002677 @default.
• W4367721052 hasRelatedWork W2094286455 @default.
• W4367721052 hasRelatedWork W2106659439 @default.
• W4367721052 hasRelatedWork W2143242056 @default.
• W4367721052 hasRelatedWork W2185625286 @default.
• W4367721052 hasRelatedWork W2621405954 @default.
• W4367721052 hasRelatedWork W2951281702 @default.
• W4367721052 hasRelatedWork W2979405718 @default.
• W4367721052 isParatext "false" @default.
• W4367721052 isRetracted "false" @default.
• W4367721052 workType "article" @default.